Effects of Tacrolimus Ointment on Facial Eruption, Itch, and Scratching in Patients with Atopic Dermatitis

Journal of Dermatology

Volumn 31, Issue 3, 2004, Pages 194-199

  Katoh, Norito ^a   Hirano, Shinya ^a   Yasuno, Hirokazu ^a   Kishimoto, Saburo ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

Author keywords

Eczema; Facial involvement; Nerve; Pruritus

Indexed keywords

ANTIHISTAMINIC AGENT; STEROID; TACROLIMUS; TRIAMCINOLONE ACETONIDE;

ADULT; ANALYSIS OF VARIANCE; ARTICLE; ATOPIC DERMATITIS; CLINICAL TRIAL; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; FACE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRURITUS; RASH; SCORING SYSTEM; SCRATCHING; STATISTICAL SIGNIFICANCE;

EID: 1842787453     PISSN: 03852407     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1346-8138.2004.tb00656.x     Document Type: Article

References (17)

1. Leung DYM: Atopic dermatitis: The skin as a window into the pathogenesis of chronic allergic disease, J Allergy Clin Immunol, 96: 302-319, 1995.
2. Klein PA, Clark RAF: An evidence-based review of the efficacy of antihistamines in relieving pruritus in atopic dermatitis, Arch Dermatol, 135: 1522-1525, 1999.
3. Yosipovitch G, Szolar C, Hui XY, Maibach H: High-potency topical corticosteroid rapidly decreases histamine-induced itch but not thermal sensation and pain in human beings, J Am Acad Dermatol, 35: 118-120, 1996.
4. Goto T, Kino T, Hatanaka H, et al: Discovery of FK-506, a novel immunosuppressant isolated from Streptomyces tsukubaensis, Transplant Proc, 19: 4-8, 1987.
5. Sawada S, Suzuki G, Kawase Y, Takaku F: Novel immunosuppressive agent, FK506. In vitro effects on the cloned T cell activation, J Immunol, 139: 1797-1803, 1987.
6. Bieber T: Topical tacrolimus (FK 506): A new milestone in the management of atopic dermatitis, J Allergy Clin Immunol, 102: 555-557, 1998.
7. Ruzicka T, Bieber T, Schopf E, et al: A short-term trial of tacrolimus ointment for atopic dermatitis. European Tacrolimus Multicenter Atopic Dermatitis Study Group, N Engl J Med, 337: 810-821, 1997.
8. Sugiura H, Uehara M, Hoshino N, Yamaji A: An open study of a lotion formulation to improve tolerance of tacrolimus in facial dermatitis, Br J Dermatol, 145: 795-798, 2001.
9. Kawakami T, Soma Y, Morita E, et al: Safe and effective treatment of refractory facial legions in atopic dermatitis using topical tacrolimus following corticosteroid discontinuation, Dermatology, 203: 32-37, 2001.
10. Hanifin JM, Rajka G: Diagnostic features of atopic dermatitis, Acta Derm Venereol, 92 (Suppl): 44-47, 1980.
11. Katoh N, Hirano S, Suehiro M, et al: Soluble CD30 is more relevant to disease activity of atopic dermatitis than soluble CD26, Clin Exp Immunol, 121: 187-192, 2000.
12. de-Paulis A, Cirillo R, Ciccarelli A, de-Crescenzo G, Oriente A, Marone G: Characterization of the anti-inflammatory effect of FK-506 on human mast cells, J Immunol, 147: 4278-4285, 1991.
13. Ito F, Toyota N, Sakai H, Takahashi H, Iizuka H: FK506 and cyclosporin A inhibit stem cell factor-dependent cell proliferation/survival, while inducing upregulation of c-kit expression in cells of the mast cell line MC/9, Arch Dermatol Res, 291: 275-283, 1999.
14. Steiner JP, Dawson TM, Fotubi M, Snyder SH: Immunophilin regulation of neurotransmitter release, Mol Med, 2: 325-333, 1996.
15. Toyoda M, Morohashi M: Morphological assessment of the effects of cyclosporin A on mast cell-nerve relationship in atopic dermatitis, Acta Derm Venereol, 78: 321-325, 1998.
16. Wahlgren CF, Scheynius A, Hagermark O: Antipruritic effect of oral cyclosporin A in atopic dermatitis, Acta Derm Venereol, 70: 322-329, 1990.
17. Hanifin JM, Ling MR, Langley R, Breneman D, Rafal E, and the Tacrolimus Ointment Study Group: Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: Part I, Efficacy, J Am Acad Dermatol, 44: s28-s38, 2001.